• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JAMA Dermatol . Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pand

tetano

Editor, Senior Moderator
JAMA Dermatol


. 2020 Nov 25.
doi: 10.1001/jamadermatol.2020.4324. Online ahead of print.
Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic


Thomas Hubiche[SUP] 1 [/SUP], Nathalie Cardot-Leccia[SUP] 2 [/SUP], Florence Le Duff[SUP] 1 [/SUP], Barbara Seitz-Polski[SUP] 3 [/SUP], Pascal Giordana[SUP] 4 [/SUP], Christine Chiaverini[SUP] 1 [/SUP], Val?rie Giordanengo[SUP] 5 6 [/SUP], G?raldine Gonfrier[SUP] 5 [/SUP], Vincent Raimondi[SUP] 7 [/SUP], Olivier Bausset[SUP] 7 [/SUP], Zoubir Adjtoutah[SUP] 7 [/SUP], Margaux Garnier[SUP] 1 [/SUP], Fanny Burel-Vandenbos[SUP] 2 [/SUP], B?reng?re Dadone-Montaudi?[SUP] 2 8 9 [/SUP], V?r?na Fassbender[SUP] 4 [/SUP], Aur?lia Palladini[SUP] 1 [/SUP], Johan Courjon[SUP] 10 [/SUP], V?ronique Mondain[SUP] 10 [/SUP], Julie Contenti[SUP] 11 [/SUP], Jean Dellamonica[SUP] 12 [/SUP], Georges Leftheriotis[SUP] 4 [/SUP], Thierry Passeron[SUP] 1 6 [/SUP]



Affiliations

Abstract

Importance: Chilblain-like lesions have been reported during the coronavirus 2019 (COVID-19) pandemic. The pathophysiology of such manifestations remains largely unknown.
Objective: To perform a systematic clinical, histologic, and biologic assessment in a cohort of patients with chilblain-like lesions occurring during the COVID-19 pandemic.
Design, setting, and participants: In this prospective case series carried out with a COVID-19 multidisciplinary consultation group at the University Hospital of Nice, France, 40 consecutive patients presenting with chilblain-like lesions were included.
Main outcomes and measures: Patients underwent a thorough general and dermatologic examination, including skin biopsies, vascular investigations, biologic analyses, interferon-alpha (IFN-α) stimulation and detection, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) and serologic analysis.
Results: Overall, 40 consecutive patients with chilblain-like lesions were included. Most patients were young, with a median (range) age of 22 (12-67) years; 19 were male and 21 were female. The clinical presentation was highly reproducible with chilblain-like lesions mostly on the toes. Bullous and necrotic evolution was observed in 11 patients. Acrocyanosis or cold toes were reported in 19 (47.5%) cases. Criteria compatible with COVID-19 cases were noted in 11 (27.5%) within 6 weeks prior to the eruption. The real-time PCR (rt-PCR) testing results were negative in all cases. Overall, SARS-CoV-2 serology results were positive in 12 patients (30%). D-dimer concentration levels were elevated in 24 (60.0%) cases. Cryoglobulinemia and parvovirus B19 serologic results were negative for all tested patients. The major histologic findings were features of lymphocytic inflammation and vascular damage with thickening of venule walls and pericyte hyperplasia. A significant increase of IFN-α production after in vitro stimulation was observed in the chilblain population compared with patients with mild-severe acute COVID-19.
Conclusions and relevance: Taken together, our results suggest that chilblain-like lesions observed during the COVID-19 pandemic represent manifestations of a viral-induced type I interferonopathy.
 
Back
Top Bottom